RESTASIS

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Ecuador, Hong Kong SAR China, Israel, Mexico, Turkey.

Active ingredients

The drug RESTASIS contains one active pharmaceutical ingredient (API):

1	Ciclosporin UNII 83HN0GTJ6D - CYCLOSPORINE
	Ciclosporin (also known as ciclosporin A) is a cyclic polypeptide immunomodulator with immunosuppressant properties. It has been shown to prolong survival of allogeneic transplants in animals and significantly improved graft survival in all types of solid organ transplantation in man. Ciclosporin has also been shown to have an anti-inflammatory effect.
	Read more about Ciclosporin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RESTASIS Emulsion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AD01	Ciclosporin	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AD Calcineurin inhibitors
Discover more medicines within L04AD01
S01XA18	Ciclosporin	S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501005002176313
CA	Health Products and Food Branch	02355655, 02476835
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.638-04-04
HK	Department of Health Drug Office	57837
IL	מִשְׂרַד הַבְּרִיאוּת	7088
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	484M2003
TR	İlaç ve Tıbbi Cihaz Kurumu	8699490546017
US	FDA, National Drug Code	0023-5301, 0023-9163, 50090-1242, 50090-4476